With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

The Centers for Medicare & Medicaid Services said on Friday that the ... in case an agreement is not reached after the ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ... Pharmaceuticalscategory· March 11, 2025 Novo Nordisk's new obesity drug trial data disappoints ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

In today's Pharmalittle roundup, we're reading about Medicare negotiations, U.K. drug rebates rising, and more.

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...